Paradigm Well being, looking for to make use of AI to enroll medical trials, companions with Roche
When folks speak about utilizing synthetic intelligence to rework the best way medicines are studied, they usually think about high-powered computer systems changing any have to experiment on people.
However a startup, Paradigm Well being, has raised $253 million primarily based on a special proposition — that AI could make the method of standing up medical trials inexpensive, sooner, and extra honest.
On Thursday, Paradigm introduced two steps towards this purpose: It stated it has raised one other $77 million from traders together with ARCH and Common Catalyst, and it has acquired a enterprise from Flatiron Well being, a unit of the drug large Roche, that was looking for to do the same factor.
This text is unique to STAT+ subscribers
Unlock this text — and get further evaluation of the applied sciences disrupting well being care — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
